PHASE 3 STUDY INVESTIGATES SLE TX.

Detalles Bibliográficos
Publicado en:Dermatology Times Vol. 39; no. 5; p. 14
Formato: brief item Journal Article
Publicado: MJH Life Sciences May2018
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=129524631&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 129524631
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        01966197
        DTI
      jtl: Dermatology Times
      issn: 01966197
      maglogo: N
    pubinfo:
      dt: May2018
      vid: 39
      iid: 5
      pid: 54670
      pub: MJH Life Sciences
      place: Cranbury, New Jersey
    artinfo:
      ui:
        129524631
        129524631
        129524631
        129524631
      ppf: 14
      ppct: 0
      formats:
      tig:
        atl: PHASE 3 STUDY INVESTIGATES SLE TX.
      aug:
      sug:
        subj:
          Belimumab Therapeutic Use
          Rituximab Therapeutic Use
          Lupus Erythematosus, Systemic Drug Therapy
          Drug Combinations
      pubtype: Trade Publication
      doctype:
        brief item
        Journal Article
      ougenre: Article
      ab:
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N